Italia markets close in 1 hour 27 minutes

Cardinal Health, Inc. (0HTG.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
111,80-0,34 (-0,31%)
In data: 02:44PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente112,14
Aperto112,36
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno111,26 - 112,36
Intervallo di 52 settimane68,75 - 116,08
Volume353
Media Volume1.140
Capitalizzazione332,71M
Beta (5 anni mensile)0,69
Rapporto PE (ttm)N/D
EPS (ttm)-3,38
Prossima data utili02 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Privia Health Announces Changes to Board of Directors

    Distinguished Healthcare Leader Dave Wichmann and Seasoned CHRO Pam Kimmet to Join BoardARLINGTON, Va., July 31, 2023 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced the election of David S. Wichmann and Pamela O. Kimmet to its Board of Directors, effective August 1, 2023. Jeff Bernstein, Managing Director of Goldman Sachs, will resign from the Board effective August 1, 2023, following Goldman Sachs’ sale of its ownership position in Privia Health through a secondary

  • GlobeNewswire

    Sotera Health Announces Jon Lyons as New Senior Vice President and Chief Financial Officer

    CLEVELAND, June 26, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced that Jon Lyons has joined the Company, effective today, as Senior Vice President and Chief Financial Officer (“CFO”). Mr. Lyons recently served as Vice President, Corporate FP&A for Owens Corning (NYSE: OC), a nearly $10 billion global building and constructio

  • GlobeNewswire

    Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner

    Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapiesInnovative Depot Model intended to reduce delivery time by allowing for transit while product release is finalized LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has selected Cardinal Health Inc. (NYSE: CAH) to support the launc